Bolt Biotherapeutics (NASDAQ:BOLT) CEO William Quinn Sells 6,545 Shares of Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) CEO William Quinn sold 6,545 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $3.32, for a total transaction of $21,729.40. Following the transaction, the chief executive officer directly owned 34,516 shares in the company, valued at $114,593.12. This trade represents a 15.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bolt Biotherapeutics Stock Up 0.8%

Shares of BOLT traded up $0.03 during trading hours on Monday, hitting $3.59. The stock had a trading volume of 22,454 shares, compared to its average volume of 27,365. Bolt Biotherapeutics, Inc. has a 1-year low of $3.10 and a 1-year high of $7.20. The firm has a market capitalization of $6.93 million, a P/E ratio of -0.22 and a beta of 1.09. The firm has a 50 day simple moving average of $3.84 and a 200-day simple moving average of $4.29. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. Sell-side analysts predict that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several large investors have recently added to or reduced their stakes in BOLT. Nan Fung Group Holdings Ltd acquired a new position in Bolt Biotherapeutics during the 2nd quarter valued at about $19,250. Renaissance Technologies LLC raised its stake in shares of Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after purchasing an additional 22,200 shares during the last quarter. Finally, T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth approximately $208,000. Institutional investors own 86.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.